Ratifi Español Sign in
Ratifi

Federal bills from Congress.gov. State bills from Open States.

S 493Session 2025-2026

Requires health practitioners to discuss with patients the risks associated with certain pain medications before prescribing such medications

S493

Underlined text would be added to current law. Struck-through text would be removed.

Skip to main content

New York State Assembly

Speaker Carl E. Heastie

  • Assembly Members
  • Legislative Info
  • Public Hearings
  • Speaker's Press
  • Assembly Reports
  • Committees & More
  • Bill Search Home
  • Laws
  • Legislative Calendar
  • Public Hearing Schedule
  • Assembly Calendars
  • Assembly Committee Agenda
Javascript must be enabled to properly view this page. Bill No.:  
     
  •  Summary 
  •  
  •  Actions 
  •  
  •  Committee&nbspVotes 
  •  
  •  Floor&nbspVotes 
  •  
  •  Memo 
  •  
  •  Text 
  •  
  •  LFIN 
  •  
  •  Chamber&nbspVideo/Transcript 

S00493 Summary:

BILL NOS00493
 
SAME ASSAME AS A03116
 
SPONSORFERNANDEZ
 
COSPNSRBORRELLO
 
MLTSPNSR
 
Add ??3309-c & 3309-d, Pub Health L
 
Requires health practitioners to discuss with patients the risks associated with certain pain medications before prescribing such medications; requires that for the first opioid analgesic prescription of a calendar year the prescribing physician shall counsel the patient on the risks of overdose.
Go to top

S00493 Text:

STATE OF NEW YORK ________________________________________________________________________ 493 2025-2026 Regular Sessions IN SENATE (Prefiled) January 8, 2025 ___________ Introduced by Sens. FERNANDEZ, BORRELLO -- read twice and ordered print- ed, and when printed to be committed to the Committee on Health AN ACT to amend the public health law, in relation to requiring health practitioners to discuss with patients the risks associated with certain pain medications before prescribing such medications; and in relation to opioid analgesic prescriptions The People of the State of New York, represented in Senate and Assem- bly, do enact as follows: 1 Section 1. The public health law is amended by adding a new section 2 3309-c to read as follows: 3 § 3309-c. Practitioner and patient discussions; opioid prescriptions. 4 1. Prior to issuing the initial prescription of a Schedule II controlled 5 substance for the treatment of pain or any other opioid drug which is a 6 prescription drug for acute or chronic pain and again prior to issuing 7 the third prescription of the course of treatment, a practitioner shall 8 discuss with the patient, or the patient's parent or guardian if the 9 patient is under eighteen years of age and is not an emancipated minor, 10 the risks associated with the drugs being prescribed, including but not 11 limited to: 12 (a) the risks of addiction and overdose associated with opioid drugs 13 and the dangers of taking opioid drugs with alcohol, benzodiazepines and 14 other central nervous system depressants; 15 (b) the reasons why the prescription is necessary; 16 (c) alternative treatments that may be available; and 17 (d) the risks associated with the use of the drugs being prescribed, 18 specifically that opioids are highly addictive, even when taken as 19 prescribed, that there is a risk of developing a physical or psycholog- 20 ical dependence on the controlled substance, and that the risks of 21 taking more opioids than prescribed, or mixing sedatives, benzodiaze- EXPLANATION--Matter in italics (underscored) is new; matter in brackets [ ] is old law to be omitted. LBD01849-01-5 S. 493 2 1 pines or alcohol with opioids, can result in fatal respiratory 2 depression. 3 2. The department shall develop and make available to practitioners 4 guidelines for the discussion required by this section. 5 § 2. The public health law is amended by adding a new section 3309-d 6 to read as follows: 7 § 3309-d. Opioid analgesic prescription. 1. For the first opioid anal- 8 gesic prescription of a calendar year that is greater than a one week's 9 supply, the prescribing physician shall counsel the patient on the risks 10 of overdose, and inform the patient of the availability of an opioid 11 antagonist, including, but not limited to, naloxone. 12 2. For the purposes of this section, the following terms shall have 13 the following meanings: 14 (a) "Opioid analgesics" means the medicines buprenorphine, butorpha- 15 nol, codeine, hydrocodone, hydromorphone, levorphanol, meperidine, 16 methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, 17 propoxyphene as well as their brand names, isomers and combinations. 18 (b) "Opioid antagonist" means an FDA-approved drug that, when adminis- 19 tered, negates or neutralizes in whole or in part the pharmacological 20 effects of an opioid in the body. The opioid antagonist is limited to 21 naloxone or other medications approved by the department for this 22 purpose. 23 § 3. This act shall take effect on the one hundred twentieth day after 24 it shall have become a law. Effective immediately, the addition, amend- 25 ment and/or repeal of any rule or regulation necessary for the implemen- 26 tation of this act on its effective date are authorized to be made and 27 completed on or before such effective date. Go to top <link href="/styles/noscript_styles.css" rel="stylesheet"/> Sitemap Request Information Directions and Maps

Official text from the New York Legislature. Formatting has been adapted for reading on Ratifi.